Patents by Inventor Frank Osterkamp
Frank Osterkamp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10799605Abstract: The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.Type: GrantFiled: June 10, 2015Date of Patent: October 13, 2020Assignee: 3B Pharmaceuticals GMBHInventors: Frank Osterkamp, Christian Haase, Ulrich Reineke, Christiane Smerling, Matthias Paschke, Jan Ungewiß
-
Patent number: 10800816Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: November 16, 2017Date of Patent: October 13, 2020Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
-
Publication number: 20190134147Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.Type: ApplicationFiled: January 14, 2019Publication date: May 9, 2019Applicants: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 10201586Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.Type: GrantFiled: December 9, 2016Date of Patent: February 12, 2019Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 10196423Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: May 9, 2018Date of Patent: February 5, 2019Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Helberg
-
Publication number: 20180334477Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: May 9, 2018Publication date: November 22, 2018Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Helberg
-
Patent number: 10124033Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.Type: GrantFiled: August 19, 2016Date of Patent: November 13, 2018Assignees: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
-
Publication number: 20180155399Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: November 16, 2017Publication date: June 7, 2018Applicants: Baxalta GmbH, Baxalta IncorporatedInventors: Michael DOCKAL, Rudolf HARTMANN, Friedrich SCHEIFLINGER, Frank OSTERKAMP, Thomas POLAKOWSKI, Ulrich REINEKE
-
Patent number: 9982016Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: July 10, 2017Date of Patent: May 29, 2018Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 9873720Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: December 29, 2014Date of Patent: January 23, 2018Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
-
Publication number: 20170313743Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: July 10, 2017Publication date: November 2, 2017Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 9745344Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: August 12, 2015Date of Patent: August 29, 2017Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20170174727Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: December 29, 2014Publication date: June 22, 2017Applicants: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: MICHAEL DOCKAL, RUDOLF HARTMANN, FRIEDRICH SCHEIFLINGER, FRANK OSTERKAMP, THOMAS POLAKOWSKI, ULRICH REINEKE
-
Publication number: 20170157198Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.Type: ApplicationFiled: December 9, 2016Publication date: June 8, 2017Applicants: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Publication number: 20170119913Abstract: The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.Type: ApplicationFiled: June 10, 2015Publication date: May 4, 2017Inventors: Frank Osterkamp, Christian Haase, Ulrich Reineke, Christiane Smerling, Matthias Paschke, Jan Ungewiß
-
Publication number: 20170035835Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.Type: ApplicationFiled: August 19, 2016Publication date: February 9, 2017Inventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
-
Patent number: 9556230Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: April 2, 2015Date of Patent: January 31, 2017Assignees: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 9458198Abstract: Disclosed are cyclic, peptide-based novel compounds having NPR-B agonistic activity. Preferred compounds are cyclic peptides containing conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. In some embodiments, provided herein are a cyclic peptide compound with a ring size that is significantly reduced as compared to known NPR-B agonists, such as CNP.Type: GrantFiled: June 12, 2013Date of Patent: October 4, 2016Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 9447147Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.Type: GrantFiled: February 27, 2015Date of Patent: September 20, 2016Assignees: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
-
Patent number: 9169293Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: August 28, 2013Date of Patent: October 27, 2015Assignee: Shire Orphan Thereapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg